Intelligent enterprise services

Intelligent city management

Intelligent car travel

Intelligent personal life

Platform Introduction

iCarbonX integrates a number of cutting-edge omics technologies, such as genomics, proteomics, metabolomics, microbiomics, epiomics and phenotypic analysis, to build a unique digital life multi-omics Comprehensive analysis platform. Since 2019, our company has shifted its business focus to innovative research in biomarker discovery, thereby assisting our partners' research efforts and transforming basic scientific research results into clinical diagnostic applications.

Fight cancer, iCarbon Cloud multi-omics comprehensive platform helps you move forward

According to the International Agency for Research on Cancer (IARC), in 2020 alone, doctors in China diagnosed as many as 4.5 million new patients with various cancers; 3 million of them died from their diseases. Like other diseases, cancer afflicts humans regardless of geographical location. Therefore, cancer has undoubtedly become the leading cause of death worldwide, with nearly 10 million deaths worldwide in 2020.

Cancer is one of the most critical public health problems globally, and advances in the availability and accuracy of early screening and diagnosis are urgently needed to enable early intervention. Compared with developed countries, China and other developing countries will benefit more from advances in early cancer screening technology because a significantly higher proportion of cancer patients in these countries are diagnosed at a later stage of tumor progression.

Our digital life multi-omics comprehensive analysis research platform helps clinicians comprehensively analyze cancer patients and cross-validate biomedical markers across multiple molecular levels, which can distinguish truly meaningful markers from false signals. For example, lung cancer is the leading cause of cancer death worldwide in 2020. [2] In fact, lung cancer is discovered when the tumor is still small or before the cancer cells spread, and the patient's chance of receiving effective treatment will be greatly increased. [3] According to the Centers for Disease Control, the only currently recommended lung cancer screening test is low-dose computed tomography (LDCT)

Leveraging lung cancer-related multidimensional biomarker clusters discovered on our comprehensive multi-omics platform, combined with LDCT screening, leading research hospitals have been able to analyze their longitudinal cohorts and differentiate malignancy with an unprecedented 89%-91% accuracy Early pulmonary nodules.
​